Ignite Creation Date:
2024-05-06 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 2:22 PM
Study NCT ID:
NCT05203445
Status:
RECRUITING
Last Update Posted:
2024-01-25
First Post:
2022-01-10
Brief Title:
A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer TNBC or Hormone Receptor-positive HER2-negative Breast Cancer
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-01-31
Start Date Type:
ACTUAL
Primary Completion Date:
2026-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-01-10
First Submit QC Date:
January 10 2022
Study First Post Date:
2022-01-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-01-24
Last Update Post Date:
2024-01-25
Last Update Post Date Type:
ACTUAL